The start of the clinical validation study represents an important step in the development of KidneyIntelX™, the company’s AI-enabled diagnostic for fast-progressing chronic kidney disease (CKD). KidneyIntelX™, which is being developed in close collaboration with Mount Sinai Health System (a leading US healthcare group), addresses a substantial unmet need: CKD affects approximately 30m people in the US alone, most commonly as a result of diabetes and/or hypertension. Often asymptomatic until 70-80% of kidney function has been lost, and with an unpredictable progression rate, CKD is associated with significant morbidity, mortality and healthcare cost. We look forward to the result of the validation study with anticipation.
